Limits...
Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma.

Paik EK, Kim MS, Jang WI, Seo YS, Cho CK, Yoo HJ, Han CJ, Park SC, Kim SB, Kim YH - Radiat Oncol (2016)

Bottom Line: The corresponding 5-year OS rates were 50 %, 58 %, 53 %, and 28 %, respectively.Patients treated with SABR after incomplete TACE had similar survival outcomes to those achieving complete response to TACE or receiving curative treatments.Therefore, if SABR was indicated at the initial diagnosis, it might be recommended after TACE failure.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul, Republic of Korea. ekpaik@kirams.re.kr.

ABSTRACT

Background: This study aimed to evaluate the effect of stereotactic ablative radiotherapy (SABR) after incomplete transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients.

Methods: The study enrolled 178 HCC patients initially treated with TACE between 2006 and 2011. Patients were included if they had Barcelona Clinic Liver Cancer stage 0 or A, ≤3 nodules with a total sum of longest diameter ≤10 cm, Child-Turcotte-Pugh score of ≤7, no major vessel invasion, and no extra-hepatic metastases.

Results: Twenty-four patients achieved a complete response to TACE (group 1). Among those with incomplete response, 47 patients received other curative treatments (group 2), 37 received SABR (group 3), and 70 received non-curative treatments (group 4). The 2-year overall survival (OS) rates for groups 1, 2, 3, and 4 were 88 %, 81 %, 73 %, and 54 %, respectively. The corresponding 5-year OS rates were 50 %, 58 %, 53 %, and 28 %, respectively.

Conclusions: Patients treated with SABR after incomplete TACE had similar survival outcomes to those achieving complete response to TACE or receiving curative treatments. However, patients receiving non-curative treatments had significantly lower survival rates than the other groups. Therefore, if SABR was indicated at the initial diagnosis, it might be recommended after TACE failure.

No MeSH data available.


Related in: MedlinePlus

Patients’ overall survival for each treatment group from the time of the first TACE treatment. No significant differences in overall survival rates were observed among groups 1, 2, and 3. However, group 4 showed a significantly inferior overall survival rate compared with the other 3 groups. Abbreviations: TACE, transcatheter arterial chemoembolization; Tx, treatment; SABR, stereotactic ablative radiotherapy
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4759954&req=5

Fig3: Patients’ overall survival for each treatment group from the time of the first TACE treatment. No significant differences in overall survival rates were observed among groups 1, 2, and 3. However, group 4 showed a significantly inferior overall survival rate compared with the other 3 groups. Abbreviations: TACE, transcatheter arterial chemoembolization; Tx, treatment; SABR, stereotactic ablative radiotherapy

Mentions: The median follow up duration after the initial TACE for all patients was 35 months (range, 2–83 months). The OS rates at 2 and 5 years were 88 % and 50 % for group 1, 81 % and 58 % for group 2, 73 % and 53 % for group 3, and 54 % and 28 % for group 4, respectively (Fig. 3). No significant differences in OS rates were observed among groups 1, 2, and 3. However, group 4 showed a significantly different OS rate compared with the other 3 groups (vs. group 1, P = 0.010; vs. group 2, P = 0.001; vs. group 3, P = 0.040; Table 2).Fig. 3


Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma.

Paik EK, Kim MS, Jang WI, Seo YS, Cho CK, Yoo HJ, Han CJ, Park SC, Kim SB, Kim YH - Radiat Oncol (2016)

Patients’ overall survival for each treatment group from the time of the first TACE treatment. No significant differences in overall survival rates were observed among groups 1, 2, and 3. However, group 4 showed a significantly inferior overall survival rate compared with the other 3 groups. Abbreviations: TACE, transcatheter arterial chemoembolization; Tx, treatment; SABR, stereotactic ablative radiotherapy
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4759954&req=5

Fig3: Patients’ overall survival for each treatment group from the time of the first TACE treatment. No significant differences in overall survival rates were observed among groups 1, 2, and 3. However, group 4 showed a significantly inferior overall survival rate compared with the other 3 groups. Abbreviations: TACE, transcatheter arterial chemoembolization; Tx, treatment; SABR, stereotactic ablative radiotherapy
Mentions: The median follow up duration after the initial TACE for all patients was 35 months (range, 2–83 months). The OS rates at 2 and 5 years were 88 % and 50 % for group 1, 81 % and 58 % for group 2, 73 % and 53 % for group 3, and 54 % and 28 % for group 4, respectively (Fig. 3). No significant differences in OS rates were observed among groups 1, 2, and 3. However, group 4 showed a significantly different OS rate compared with the other 3 groups (vs. group 1, P = 0.010; vs. group 2, P = 0.001; vs. group 3, P = 0.040; Table 2).Fig. 3

Bottom Line: The corresponding 5-year OS rates were 50 %, 58 %, 53 %, and 28 %, respectively.Patients treated with SABR after incomplete TACE had similar survival outcomes to those achieving complete response to TACE or receiving curative treatments.Therefore, if SABR was indicated at the initial diagnosis, it might be recommended after TACE failure.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul, Republic of Korea. ekpaik@kirams.re.kr.

ABSTRACT

Background: This study aimed to evaluate the effect of stereotactic ablative radiotherapy (SABR) after incomplete transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients.

Methods: The study enrolled 178 HCC patients initially treated with TACE between 2006 and 2011. Patients were included if they had Barcelona Clinic Liver Cancer stage 0 or A, ≤3 nodules with a total sum of longest diameter ≤10 cm, Child-Turcotte-Pugh score of ≤7, no major vessel invasion, and no extra-hepatic metastases.

Results: Twenty-four patients achieved a complete response to TACE (group 1). Among those with incomplete response, 47 patients received other curative treatments (group 2), 37 received SABR (group 3), and 70 received non-curative treatments (group 4). The 2-year overall survival (OS) rates for groups 1, 2, 3, and 4 were 88 %, 81 %, 73 %, and 54 %, respectively. The corresponding 5-year OS rates were 50 %, 58 %, 53 %, and 28 %, respectively.

Conclusions: Patients treated with SABR after incomplete TACE had similar survival outcomes to those achieving complete response to TACE or receiving curative treatments. However, patients receiving non-curative treatments had significantly lower survival rates than the other groups. Therefore, if SABR was indicated at the initial diagnosis, it might be recommended after TACE failure.

No MeSH data available.


Related in: MedlinePlus